These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20425064)

  • 1. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering.
    Ismail H; Mitchell R; McFarlane SI; Makaryus AN
    Curr Diab Rep; 2010 Feb; 10(1):32-6. PubMed ID: 20425064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.
    Angeli F; Reboldi G; Mazzotta G; Poltronieri C; Garofoli M; Ramundo E; Biadetti A; Verdecchia P
    Curr Drug Saf; 2012 Feb; 7(1):76-85. PubMed ID: 22663961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors.
    Estacio RO
    Postgrad Med; 2009 May; 121(3):33-44. PubMed ID: 19491538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical role of direct renin inhibition in hypertension.
    Taylor AA; Pool JL
    Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
    Ferrario CM
    Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized?
    Pappoe LS; Winkelmayer WC
    Drugs Aging; 2010 Feb; 27(2):87-94. PubMed ID: 20104936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.
    Sureshkumar KK
    Vasc Health Risk Manag; 2008; 4(6):1205-20. PubMed ID: 19337534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.